CoChat
Sign Up
Cited by 132Sexual function and dysfunction studiesUrological Disorders and TreatmentsUrinary Bladder and Prostate Research

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Dropout in the Treatment of Erectile Dysfunction with PDE5: A Study on Predictors and a Qualitative Analysis of Reasons for Discontinuation

Open access
Carvalheira, Ana A., Pereira, Nuno Monteiro, Maroco, João, Forjaz, Vera·2012·The Journal of Sexual Medicine
DOI 10.1111/j.1743-6109.2012.02787.x
Open this paper in CoChat — free account

Abstract

INTRODUCTION: Phosphodiesterase type 5 inhibitors (PDE5) are currently the first line treatment for erectile dysfunction (ED). However, previous research shows that PDE5 treatments have high discontinuation rates. Understanding the reasons for discontinuing PDE5 will be necessary to optimize the response to treatment. AIM: The main goals were: (i) to analyze discontinuation rate of PDE5; (ii) to identify the discontinuation predictors; and (iii) to study the reasons for discontinuation using a qualitative methodology. MAIN OUTCOME MEASURES: The PDE5 discontinuation rates, predictors, and reasons for discontinuation treatment. METHODS: A total of 327 men with clinical diagnosis for ED who had been treated with PDE5 were successfully interviewed by telephone, after giving their informed consent by snail mail. Telephone interviews, concerning their ongoing treatment, were carried out using a standardized questionnaire form with quantitative and qualitative items. Participation rate was 71.8%. RESULTS: Of the total sample, 160 men (48.9%) had discontinued PDE5 treatment. The discontinuation rate was higher among men with diabetes (73%) and in iatrogenic group (65%), and lower in venogenic etiology (38.7%). We differentiated three groups of men who discontinued treatment (i) during the first 3 months (55.1%); (ii) between 4 and 12 months (26.9%); and (iii) after a period of 12 months (18%). Qualitative analyses revealed diverse reasons for discontinuation: non-effectiveness of PDE5 (36.8%), psychological factors (e.g., anxiety, negative emotions, fears, concerns, dysfunctional beliefs) (17.5%), erection recovery (14.4%), and concerns about the cardiovascular safety of PDE5 (8.7%) were the most common. Older men and men whose partners were involved in the treatment, were less likely to discontinue treatment. CONCLUSION: Half the subjects discontinued medication. Mostly, there was a combination of factors that led to discontinuation: non-effectiveness and psychosocial factors appear to be the main reasons. Addressing those factors will allow following up with appropriate focus on relevant topics in order to improve compliance.

Overview

Integrity signals

Registry

Crossref · 10.1111/j.1743-6109.2012.02787.x

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 26 references

Research works printed but not linked: 2

  1. Basar, 2003, Causes of sildenafil citrate treatment discontinuation in erectile dysfunction patients (poster section P-026), Int J Impot Res, 15, S51
  2. Casabe, 2001, Drop out reasons in responders to sildenafil (moderated poster 9), Int J Impot Res, 13, S5

Cited by

Sorted by citations

Items 101–132 of 132

Related

See all

Metadata

Authors
Carvalheira, A. A., Pereira, N. M., Maroco, J., & Forjaz, V.
Affiliations
  • Research Unit of Psychology and Health, University Institute of Applied Psychology , Lisbon , Portugal
  • iSex—Association for the Advanced Study of Human Sexuality, ULHT , Lisbon , Portugal
Corresponding author
Carvalheira, Ana A.
ORCID
Venue
The Journal of Sexual Medicine
Publisher
Oxford University Press (OUP)
Published
2012-09-01
Volume
9
Issue
9
Pages
2361-2369
ISSN
  • 1743-6095 (ISSN-L)
  • 1743-6109
DOI
10.1111/j.1743-6109.2012.02787.x
OpenAlex
W1514818611
Cited by
132
References
26
Citations by year
2026: 2 · 2025: 7 · 2024: 6 · 2023: 8 · 2022: 9 · 2021: 8 · 2020: 13 · 2019: 11 · 2018: 10 · 2017: 12 · 2016: 12 · 2015: 15 · 2014: 13 · 2013: 4 · 2012: 2
FWCI
7.77
Type
journal article
Language
en
Open access
Licence
Locations
  • The Journal of Sexual Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion)
  • Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
Funders
Pfizer
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Sexual function and dysfunction studies
  • Health Sciences › Medicine › Urology › Urological Disorders and Treatments
  • Health Sciences › Medicine › Urology › Urinary Bladder and Prostate Research
Keywords
erectile dysfunction, phosphodiesterase-5 inhibitors, treatment discontinuation, predictors of discontinuation, reasons for discontinuation, treatment effectiveness, psychosocial factors, anxiety, diabetes mellitus, partner involvement, medication adherence
MeSH terms
Adult, Age Factors, Aged, Aged, 80 and over, Diabetes Mellitus, Humans, Iatrogenic Disease, Erectile Dysfunction, Male, Middle Aged, Patient Dropouts, Sexual Partners, Logistic Models, Impotence, Vasculogenic, Medication Adherence, Phosphodiesterase 5 Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review